New hope for advanced colon cancer: AK112 combo enters phase 3 trial
NCT ID NCT06951503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study compares a new drug, AK112, combined with chemotherapy against the standard treatment (bevacizumab plus chemo) for people with metastatic colorectal cancer that has not been treated before. The goal is to see if the new combination helps patients live longer without their cancer growing. About 560 adults aged 18 to 75 with good performance status are being recruited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuanzhou, Guangdong, China
-
The Sixth Hospital,Sun Yat-sen University
RECRUITINGGuanzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Breath of life: new test could sniff out gut cancers before they spread
- Gut instinct: listening to bowel sounds may reveal hidden clues about surgical recovery
- Triple therapy aims to wipe out colorectal cancer before surgery
- DNA 'Crystal Ball' may spot return of colorectal cancer